TrianglePUBLICATIONS · 39259927
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2024 Nov
- First author
- Loibl S
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Loibl S
- type
- Author
- name
- Jassem J
- type
- Author
- name
- Sonnenblick A
- type
- Author
- name
- Parlier D
- type
- Author
- name
- Winer E
- type
- Author
- name
- Bergh J
- type
- Author
- name
- Gelber RD
- type
- Author
- name
- Restuccia E
- type
- Author
- name
- Im YH
- type
- Author
- name
- Huang CS
- type
- Author
- name
- Dalenc F
- type
- Author
- name
- Calvo I
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Loibl S
- type
- Author
- name
- Jassem J
- type
- Author
- name
- Sonnenblick A
- type
- Author
- name
- Parlier D
- type
- Author
- name
- Winer E
- type
- Author
- name
- Bergh J
- type
- Author
- name
- Gelber RD
- type
- Author
- name
- Restuccia E
- type
- Author
- name
- Im YH
- type
- Author
- name
- Huang CS
- type
- Author
- name
- Dalenc F
- type
- Author
- name
- Calvo I
- type
- Author
- bibliography ids
- nci-bib-2cc5d62c3dbdacb680047cca
- book metadata
- content sha256
- efa910b9f95132d5f50e8d5a84cf99cbe963f0ff8ec95a051c01f554310b4897
- document type
- citation
- dois
- 10.1200/JCO.23.02505
- electronic publication date
- display
- 2024 Sep 11
- precision
- day
- year
- 2024
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:39259927
- immutable id
- pubmed:39259927@efa910b9f95132d5f50e8d5a84cf99cbe963f0ff8ec95a051c01f554310b4897
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 31
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 3643-3651
- volume
- 42
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 39259927
- provenance
- batch id
- 3e43afde6f26fc8df6da
- provider
- NCBI PubMed ESummary
- record sha256
- e21fc7377ade524b7fed8d9d4feb6245a7c57b38170dd3aaebbcfa5e935f1130
- response sha256
- fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
- retrieved at
- 2026-09-09T23:48:21.145285+00:00
- publication date
- display
- 2024 Nov
- precision
- month
- year
- 2024
- publication types
- Journal Article
- Randomized Controlled Trial
- Clinical Trial, Phase III
- Multicenter Study
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.
Preserved source evidence · Not medical advice